A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy

Neurology

Volumn 61, Issue 4, 2003, Pages 528-530

  Mundy, H R ^a   Jones, S J ^a   Hobart, J C ^a   Hanna, M G ^b   Lee, P J ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SNAKE VENOM;

ADRENOLEUKODYSTROPHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EVOKED BRAIN STEM AUDITORY RESPONSE; EVOKED SOMATOSENSORY RESPONSE; EVOKED VISUAL RESPONSE; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0041931042     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000079460.21925.D3     Document Type: Article

References (10)

1. Moser HW. Treatment of X-linked adrenoleukodystrophy with Lorenzo's oil. J Neurol Neurosurg Psychiatry 1999;67:279-280.
2. Teerapong P, Harvey AL, Barkas T. Neuromuscular effects of fractions isolated from the venom of the Thailand cobra, Naja naja siamensis. Toxicon 1978;16:551-560.
3. Hobart JC, Lamping DL, Fitzpatrick R, et al. Measuring the walking ability of people with multiple sclerosis (MS): a novel, patient based, and rigorous 12-item measure. Qual Life Res 2000;9:286.
4. Wade DT, Collin C. The Barthel ADL index: a standard measure of physical disability? Int Disabil Stud 1988;10:64-67.
5. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
6. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483.
7. Fisher JS, Rudick RA, Cutter GR, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244-250. Review.
8. Brusa A, Mortimer C, Jones S. Clinical evaluation of VEPs to interleaved checkerboard reversal stimulation of central, hemi- and peripheral fields. Electroencephalogr Clin Neurophysiol 1995;96:485-494.
9. Van Geel BM, Assies J, Haverkort EB, et al. Progression of abnormalities in adrenomyeloneuropatby in asyinptomatic X-linked adrenoleukodystrophy despite treatment with Lorenzo's oil. J Neurol Neurosurg Psychiatry 19999;67:290-299.
10. Singh I, Ehan M, Key L, et al. Lovastatin for X-linked adrenoleukodystrophy. N Engl J Med 1998 339;702-703.